Search

Home > News & Events > Current News
New Gobal commitment to end TB
Monday, November 20, 2017 - 08:30

On Friday 17 November 75 ministers announced a landmark agreement to take urgent action to end tuberculosis (TB) by 2030 at the conclusion of a World Health Organization (WHO) conference in Moscow, Russia, on eradicating the world's deadliest infectious disease.

Progression from infection to Pulmonary Tuberculosis follows distinct timeline
Friday, November 17, 2017 - 08:15

SATVI researchers have uncovered a sequence of biological processes that occur in humans infected with the bacterium Mycobacterium tuberculosis as the infection progresses to pulmonary tuberculosis, according to new research published in the PLOS Pathogens Journal

9 November 2017 Research Published: TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development
Thursday, November 9, 2017 - 14:15

Associate Professor Tom Scriba has collaborated with the authors of a research paper titled: "TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development" appearing in the Frontiers in Immunology Journal.

25 October 2017 Research Published Polyfunctional CD4+TCells as targets for vaccination
Monday, November 6, 2017 - 14:45

Associate Professor Tom Scriba has co authored a research paper titled "Polyfunctional CD4+T Cells as targets for Tuberculosis Vaccination" appearing in the Frontiers in Immunology Journal.

5 October 2017 RESEARCH: Safety and Immunogenicity Immunogenicity of newborn MVA 85 A vaccination and selective delayed Bacille Calmette-Guerin for infants of HIV infected mothers: a Phase 2 Randomized Controlled Trial
Thursday, October 5, 2017 - 11:30

SATVI authors Dr Elisa Nemes, Prof Mark Hatherill, Associate Prof Tom Scriba, Dr Michele Tameris, Humphrey Mulenga and Danelle Van As have published a research paper titled: "Safety and Immunogenicity of newborn MVA 85 A vaccination and selective delayed Bacille Calmette-Guerin for infants of HIV infected mothers: a Phase 2 randomized controlled trial" appearing in the Infectious Disease Journal (Oxford).

3 October 2017 Research: Host blood signatures RNA predict the outcome of tuberculosis treatment
Tuesday, October 3, 2017 - 10:30

Associate Professor Tom Scriba has co-authored a article titled: "Host blood RNA predict the outcome of tuberculosis treatment" appearing in the Tuberculosis Journal.

21 September 2017 Vacancy Research Officer: Systems Immunology
Thursday, September 21, 2017 - 18:15

SATVI invites applications for the position of Research Officer: Systems Immunology at its Cape Town offices. CLOSED.

14 September 2017 Research: Application of a whole blood mycobacterial growth inhibition assay to study immunity against Mycobacterium tuberculosis in a high tuberculosis burden population
Friday, September 15, 2017 - 09:00

SATVI authors have published a research paper titled: "Application of a whole blood mycobacterial growth inhibition assay to study immunity against Mycobacterium tuberculosis in a high tuberculosis burden population" appearing in the PLoS ONE Journal.

8 September 2017 Research: A Functional Toll-Interacting Protein Variant associated with Bacillus Calmette-Guerin Specific Immune Response and Tuberculosis
Friday, September 8, 2017 - 08:00

Professor Mark Hatherill and Associate Professor Tom Scriba have co-authored a research paper titled "A Functional Toll-interacting Protein variant with Bacillus Calmette-Guerin specific immune responses and Tuberculosis" appearing in the American Journal of Respiratory and Critical Care Medicine.

7 September 2017 Research Published: Identifying specificity groups in T cell receptor repertoire
Thursday, September 7, 2017 - 17:15

Associate Professor Tom Scriba has co-authored a research paper titled "Identifying specificity groups in the T Cell receptor repertoire" appearing in the Nature Journal.

6 September 2017 Research Published: Protein kinase C-delta (PKCd), a marker of inflammation and tuberculosis disease progression in humans, is important for optimal macrophage killing effector functions and survival in mice
Wednesday, September 6, 2017 - 20:15

SATVI authors Associate Professor Tom Scriba, Dr Stanley Mbandi Kimbung, Fatoumatta Darboe and Dr Adam Penn-Nicholson have co-authored a paper titled "Protein kinase C-delta (PKCd), a marker of inflammation and tuberculosis disease progression in humans, is important for optimal macrophage killing effector functions and survival in mice" appearing in the Mucosol Immunology Journal.

6 September 2017 SATVI marks 3000th patient screened in CORTIS HR study.
Wednesday, September 6, 2017 - 19:00

SATVI recently marked the 3 000th patient who had been screened for participation in the Correlates of Risk of TB study (CORTIS-01).  

Pages